These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17017544)

  • 21. Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
    Török N; Majláth Z; Fülöp F; Toldi J; Vécsei L
    Curr Drug Metab; 2016; 17(5):412-29. PubMed ID: 26694727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrastriatal Quinolinic Acid Administration Impairs Redox Homeostasis and Induces Inflammatory Changes: Prevention by Kynurenic Acid.
    Ferreira FS; Schmitz F; Marques EP; Siebert C; Wyse ATS
    Neurotox Res; 2020 Jun; 38(1):50-58. PubMed ID: 32219734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
    Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum.
    Urenjak J; Obrenovitch TP
    J Neurochem; 2000 Dec; 75(6):2427-33. PubMed ID: 11080194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
    Szabó N; Kincses ZT; Toldi J; Vécsei L
    J Neurol Sci; 2011 Nov; 310(1-2):256-60. PubMed ID: 21824629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
    Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
    Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kynurenine pathway in depression: A systematic review and meta-analysis.
    Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
    Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kynurenine metabolism in Alzheimer's disease.
    Baran H; Jellinger K; Deecke L
    J Neural Transm (Vienna); 1999; 106(2):165-81. PubMed ID: 10226937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
    Behl T; Kaur I; Sehgal A; Singh S; Bhatia S; Al-Harrasi A; Zengin G; Bumbu AG; Andronie-Cioara FL; Nechifor AC; Gitea D; Bungau AF; Toma MM; Bungau SG
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.
    Schwieler L; Samuelsson M; Frye MA; Bhat M; Schuppe-Koistinen I; Jungholm O; Johansson AG; Landén M; Sellgren CM; Erhardt S
    J Neuroinflammation; 2016 Feb; 13(1):51. PubMed ID: 26925576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.
    Stone TW
    Prog Neurobiol; 2001 Jun; 64(2):185-218. PubMed ID: 11240212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
    Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
    J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism.
    Fukui S; Schwarcz R; Rapoport SI; Takada Y; Smith QR
    J Neurochem; 1991 Jun; 56(6):2007-17. PubMed ID: 1827495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition.
    Phillips RS; Iradukunda EC; Hughes T; Bowen JP
    Front Mol Biosci; 2019; 6():3. PubMed ID: 30800661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.
    Chiarugi A; Moroni F
    Neuropharmacology; 1999 Aug; 38(8):1225-33. PubMed ID: 10462134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
    Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
    Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
    Bohár Z; Toldi J; Fülöp F; Vécsei L
    Int J Mol Sci; 2015 Apr; 16(5):9772-93. PubMed ID: 25938971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kynurenine and its metabolites in Alzheimer's disease patients.
    Gulaj E; Pawlak K; Bien B; Pawlak D
    Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.